Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2018

01-01-2018 | Side Effects of Endocrine Treatments

Oral mucositis induced by treatment with soft gel formulation of levothyroxine

Authors: Erika Messina, Francesco Ferraù, Salvatore Cannavò

Published in: Endocrine | Issue 1/2018

Login to get access

Excerpt

The development of the novel oral formulations of levothyroxine (LT4), i.e. liquid preparations and soft gel capsules, represents a remarkable innovation in the replacement therapy of hypothyroidism [1, 2]. These new formulations are more effective than tablets in normalizing thyrotropin (TSH) levels in hypothyroid patients with intestinal malabsorption, gastric disorders, or ingesting drugs or food known to interfere with LT4 absorption [2, 3]. Furthermore, the LT4 tablets need to be taken in a fasting state, while the new oral formulations can be directly ingested at breakfast, thus improving the therapeutic compliance. …
Literature
1.
J.V. Hennessey, The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine 55(1), 6–18 (2017)CrossRefPubMed
2.
C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine 54(1), 3–14 (2016)CrossRefPubMed
3.
A.M. Formenti, G. Mazziotti, R. Giubbini, A. Giustina, Treatment of hypothyroidism: all that glitters is gold? Endocrine 52(3), 411–413 (2016)CrossRefPubMed
4.
R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as soft gel capsule or liquid solution. Expert. Opin. Drug Deliv. 11(7), 1103–1111 (2014)CrossRefPubMed
5.
F. Lavaee, M. Majd, Evaluation of the association between oral lichen planus and hypothyroidism: a retrospective comparative study. J. Dent. (Shiraz) 17(1), 38–42 (2016)
6.
I. Ozdemir, O. Calka, A.S. Karadag, N. Akdeniz, M. Ozturk, Thyroid autoimmunity associated with recurrent aphthous stomatitis. J. Eur. Acad. Dermatol. Venereol. 26(2), 226–230 (2012)CrossRefPubMed
Metadata
Title
Oral mucositis induced by treatment with soft gel formulation of levothyroxine
Authors
Erika Messina
Francesco Ferraù
Salvatore Cannavò
Publication date
01-01-2018
Publisher
Springer US
Published in
Endocrine / Issue 1/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1312-7

Other articles of this Issue 1/2018

Endocrine 1/2018 Go to the issue

Author Correction

Correction to: Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review

Editorial

Dopamine agonist withdrawal in hyperprolactinemia: when and how

Original Article

Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome

Original Article

Oxidative stress in adult growth hormone deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome

Endocrine Trials

Metformin effect on TSH in subclinical hypothyroidism: randomized, double-blind, placebo-controlled clinical trial

Meta-Analysis

Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits